The Cancer Market Outlook to 2016

Introduction

The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. This report presents leading products, developments, and market forecasts for each of these classes. Eighteen recently launched/late-stage pipeline products are discussed in detail.

Features and benefits

* Understand how recent events are affecting the performance of major products, and how companies are confronting competitive market changes.
* Compare the franchises of the leading companies in the cancer market, and understand how the market share of these companies will change.
* Assess key pipeline products by indication, ongoing trials, recent product launches, and key developments in R&D.
* Identify the challenges faced by leading players, and understand how recent events will impact the performance of leading products.
* Gain insights into the forecasts of the leading marketed and pipeline products through to 2016.

Highlights

The key factor for growth of the cancer therapy market is the expansion of target indications. Most of the blockbuster drugs were launched for a narrow indication, but later gained approval for a wider range of indications.
Regardless of indication, the key challenge in ensuring the commercial success of pipeline drugs is to ascertain their integration into current treatment regimens either in combination with existing therapies or by demonstrating significant superiority over current treatments.
Pricing risk remains the key investment concern in cancer. Moreover, the level of scrutiny by payers regarding the cost-effectiveness of cancer treatments has intensified in recent years.

Your key questions answered

* What will be the major growth indications and the accompanying growth drivers in the cancer market over the next 6 years?
* Which were the leading players in the cancer market in 2010?
* Which products will be the future growth drivers for the cancer health market?
* Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2010–16?
* Which companies are best positioned to succeed in the cancer market over the period 2010–16?
[Studien Infos ausblenden]

Executive Summary
Overview and epidemiology of cancer
Global market analysis
Pipeline analysis
Competitive landscape
About Business Insights
Disclaimer
Overview and epidemiology of cancer
Summary
Introduction
Overview
Cancer risk factors
Chemical carcinogens
Age
Tobacco smoke
Lifestyle factors
Radiation
Immune system
Genetics
Lung cancer
Overview
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Colorectal cancer
Overview
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Breast cancer
Overview
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Ovarian cancer
Overview
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Uterine and cervical cancer
Overview
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Leukemia
Overview
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Prostate cancer
Overview
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Pancreatic cancer
Overview
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Lymphomas
Overview
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Head and neck cancer
Overview
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Global market analysis
Summary
Introduction
Market analysis by country
Market analysis by drug class
Leading brand dynamics
Avastin (bevacizumab) – Roche
Herceptin (trastuzumab) – Roche
MabThera (rituximab) – Roche
Taxotere (docetaxel) – Sanofi
Alimta (pemetrexed) – Eli Lilly
Key recent events in the cancer market
Amgen/Takeda’s motesanib fails Phase III trial in lung cancer
Merck Serono files expanded approval for Erbitux (cetuximab) in the EU
Abbott signs a deal with Seattle Genetics for antibody drug conjugate (ADC) technology
Strides’ carboplatin approved in European markets
Herceptin receives approval for gastric cancer in Japan
NICE revises its decision for MabThera as a maintenance treatment
Antineoplastics
Competitive dynamics of antineoplastics
Leading antineoplastic brands
Antineoplastic mAb market analysis
Antineoplastic sales forecast
Cytostatic hormonal therapies
Competitive dynamics of cytostatic hormonal therapies
Leading brands of cytostatic hormonal therapies
Cytostatic hormonal therapy sales forecast
Global cancer market sales forecast
Pipeline analysis
Summary
Introduction
Key trends in R&D
Targeted therapies are changing the treatment regimen of cancer
Cancer vaccines enhance the body’s immune response
Pricing is becoming a major issue for cancer patients
Combination treatments are becoming the treatment of choice
Oncology pipeline
Leading drugs in development
Recently approved/marketed drugs
Phase III compounds
Pipeline forecast of leading drugs in development
Competitive landscape
Summary
Introduction
Sales performance of leading players
Roche
Sales focus by drug class
Regional sales distribution
Leading products
Pipeline analysis
Strategic and growth analysis
Eli Lilly
Sales focus by drug class
Regional sales distribution
Leading products
Pipeline analysis
Strategic and growth analysis
AstraZeneca
Sales focus by drug class
Regional sales distribution
Leading products
Pipeline analysis
Strategic and growth analysis
Sanofi
Sales focus by drug class
Regional sales distribution
Leading products
Pipeline analysis
Strategic and growth analysis
Takeda
Sales focus by drug class
Regional sales distribution
Leading products
Pipeline analysis
Strategic and growth analysis
Appendix
Scope
Methodology
Market size methodology
Epidemiology
Market forecast
Glossary/Abbreviations
Trial expansions
References
Journal articles
Clinical trials
Important websites
[Inhaltsverzeichnis ausblenden]